June 2005
Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30    
May   Jul


For more search options, please see the Advanced search form and the section of the User's Guide, Tips for Searching PULSE.


C H A N N E L S
• PULSE Home Page
• EXECUTIVE EDITION

• US News
• Canada News
• UK News
• New Zealand News

• Consumer Advocacy
• Health Care Systems
• Managed Care/Medicaid
• Co-occurring Disorders
• Clinical studies
• Pharmaceutical News
• Criminal Justice Systems
• Legislative News


U S E R ' S   G U I D E
About PULSE
PULSE Channels
Archives
Adding comments
Using the # link
Items that require registration
PULSE syndication
Tips for Searching PULSE


E M A I L   S U B S C R I P T I O N S

For WEEKLY summaries of PULSE postings, see the weekly email subscription form.

For DAILY mailings (powered by Bloglet), please enter your e-mail address below:


P U B L I C A T I O N S

PULSE ANNUAL No. 2
January 2003

Recent Trends, Challenges and Issues in Funding Public Mental Health Services in the US
March 2002

PULSE ANNUAL No. 1
October 2001

 

PULSE is powered by
Radio Userland.

Listed on BlogShares

© Bill Davis, 2000-2003.

About PULSE | Channels | User's Guide | Email subscriptions | Publications




PULSE is a free service of the Centre for Community Change International, gathering new and noteworthy Internet resources for mental health providers, family members of individuals with mental illness, consumers of mental health services and consumer advocates. PULSE is researched, edited and designed by Bill Davis.



daily link  Thursday, June 09, 2005


Court Says OxyContin Patent Is Invalid New York Times story - "A federal appeals court found yesterday that Purdue Pharma had deliberately misled the government to win patent protection for its powerful painkiller OxyContin. The ruling, which makes patents on the drug not enforceable, opens the door to increased generic competition, as well as potentially huge legal awards against Purdue. The unanimous ruling by a three-judge panel of the United States Court of Appeals for the Federal Circuit in Washington is a victory for Endo Pharmaceuticals Holdings, which is seeking to market a generic form of OxyContin." [Viewing New York Times resources requires registration, which is free].  
permalink